Analyst Jacob Kilstein noted that the company warned last Monday after the close that third-quarter revenues would likely undershoot its target, blaming the shortfall on a greater-than-expected drop in sales of gene-sequencing machines. On Tuesday, reacting to the announcement, shares fell 25 percent intra-day.
Citing the anticipated revenue miss, Argus lowered its 2016 adjusted earnings per share estimate to $3.40 and the 2017 estimate to $4.02. Notwithstanding the current revenue weakness, Argus sees continued growth in the market for gene sequencing equipment.
As such, the firm lowered its price target on the shares to $170 from $205 but maintains its Buy rating.
At the time of writing, shares of Illumina were up 0.45 percent at $136.75.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.